<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635749</url>
  </required_header>
  <id_info>
    <org_study_id>2017YFC1307905</org_study_id>
    <nct_id>NCT03635749</nct_id>
  </id_info>
  <brief_title>Intensive Medical Therapy for High-risk Intracranial or Extracranial Arterial Stenosis</brief_title>
  <acronym>INSPIRES</acronym>
  <official_title>Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Arterial Stenosis (INSPIRES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People's Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Large-artery stenosis plays an important role in the occurrence of ischemic stroke. The&#xD;
      primary purpose of this study is to evaluate the efficacy and safety of intensive&#xD;
      antiplatelet therapy versus standard antiplatelet therapy and immediate high-intensity statin&#xD;
      therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin)&#xD;
      and intensive antiplatelet combined with immediate high-intensity statin therapy (80mg&#xD;
      atorvastatin) versus standard antiplatelet combined with delayed high-intensity statin&#xD;
      therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute&#xD;
      and high-risk symptomatic extracranial or intracranial arterial stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large-artery atherosclerotic stenosis is the main cause of ischemic stroke, especially in&#xD;
      Asian population. However, targeted treatment evidence for large-artery atherosclerotic&#xD;
      stenosis is limited according to the current guidelines. And also, randomized trial for&#xD;
      statin therapy in patients with acute large arterial stenosis at early stage is still&#xD;
      limited. The primary purpose of this study is to evaluate the efficacy and safety of&#xD;
      intensive antiplatelet therapy versus standard antiplatelet therapy in reducing the risk of&#xD;
      stroke at 90 days in patients with acute and high-risk symptomatic extracranial or&#xD;
      intracranial arterial stenosis; the efficacy and safety of immediate high-intensity statin&#xD;
      therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin)&#xD;
      in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic&#xD;
      extracranial or intracranial arterial stenosis; and the efficacy and safety of intensive&#xD;
      antiplatelet combined with immediate high-intensity statin therapy (80mg atorvastatin) versus&#xD;
      standard antiplatelet combined with delayed high-intensity statin therapy (40mg atorvastatin)&#xD;
      in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic&#xD;
      extracranial or intracranial arterial stenosis.&#xD;
&#xD;
      This trial is a randomized, double-blind, placebo-controlled, multicenter, 2×2 factorial&#xD;
      designed clinical trial. 6100 patients in 250 centers in China will be enrolled with one of&#xD;
      the following situations (1) Mild ischemic stroke (NIHSS 4~5) within 24 hours of onset meets&#xD;
      any of the following imaging conditions: a) Acute single cerebral infarction with criminal&#xD;
      intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),b) Acute multiple&#xD;
      cerebral infarction (considered to be caused by large artery atherosclerosis, including&#xD;
      non-stenotic vulnerable plaque);Or (2) Moderate-to-high-risk TIA (ABCD2≥4) or mild ischemic&#xD;
      stroke (NIHSS≤5) within 24 to 72 hours of onset meets any of the following imaging&#xD;
      conditions: a) Medium and high risk TIA with criminal intracranial and extracranial&#xD;
      atherosclerotic stenosis (stenosis rate ≥50%),b) Acute single cerebral infarction with&#xD;
      criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),c) Acute&#xD;
      multiple cerebral infarction (considered to be caused by large artery atherosclerosis,&#xD;
      including non-stenotic vulnerable plaque) . Patients will be randomly assigned into 4 groups&#xD;
      according to the ratio of 1:1:1:1:&#xD;
&#xD;
        1. Intensive antiplatelet therapy + immediate high-intensity statin therapy (80mg&#xD;
           atorvastatin)&#xD;
&#xD;
        2. Intensive antiplatelet therapy + delayed high-intensity statin therapy (40mg&#xD;
           atorvastatin)&#xD;
&#xD;
        3. Standard antiplatelet therapy + immediate high-intensity statin therapy (80mg&#xD;
           atorvastatin)&#xD;
&#xD;
        4. Standard antiplatelet therapy + delayed high-intensity statin therapy (40mg&#xD;
           atorvastatin)&#xD;
&#xD;
      Face to face interviews will be made at baseline, 7, 14 (or hospital discharge), 90 ± 7 days&#xD;
      and 12th month ± 14 days after randomization.&#xD;
&#xD;
      Survival curves will be estimated for the primary outcome using the Kaplan-Meier procedure&#xD;
      and compared using a Cox regression model Wald test, stratified by the opposite arm of the&#xD;
      factorial design. Safety outcomes will be calculated using the Kaplan-Meier curve to simulate&#xD;
      the 3-month cumulative risk, and the Cox proportional hazards model to calculate the HR and&#xD;
      95% confidence interval.&#xD;
&#xD;
      Primary outcome is defined as stroke (including hemorrhagic and ischemic stroke). Secondary&#xD;
      outcomes include composite vascular events (stroke, myocardial infarction, and cardiovascular&#xD;
      death); ischemic stroke; transient ischemic attack; myocardial infarction; vascular death;&#xD;
      all-cause death; poor functional outcome (mRS 2-6); and quality of life (EQ-5D scale). Safety&#xD;
      outcomes, relating to antiplatelet therapy (i.e. bleeding, intracranial hemorrhage, and&#xD;
      adverse events) and statin therapy (i.e. hepatotoxicity, muscle toxicity and adverse events)&#xD;
      will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The subjects are randomly assigned to the following four groups:&#xD;
Intensive antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)&#xD;
Intensive antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)&#xD;
Standard antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)&#xD;
Standard antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Two nearly identical tablet forms of Clopidogrel (75mg Clopidogrel and matching placebo) with almost the same size, color and smell will be used in this research.&#xD;
Two nearly identical tablet forms of Aspirin (100mg Aspirin and matching placebo) with almost the same size, color and smell will be used in this research.&#xD;
Two nearly identical tablet forms of Atorvastatin (20mg Atorvastatin and matching placebo) with almost the same size, color and smell will be used in this research.&#xD;
Centers are not able to apply unblinding with biological experiment in this study. Researchers shall never unblind the code unless special situations occur such as Serious Adverse Events (SAE), which is essential for treatment. Clinical outcomes of efficacy and safety are submitted to Adjudication Committee, who should be blinded to randomization, for final determination.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Symptoms and signs of acute neurological deficits caused by sudden focal or whole brain, spinal cord or retinal vascular damage, which are related to cerebral circulatory disorders, including hemorrhagic and ischemic stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite vascular events</measure>
    <time_frame>90 days</time_frame>
    <description>stroke (including hemorrhagic and ischemic stroke), myocardial infarction, and cardiovascular death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>90 days</time_frame>
    <description>An acute focal infarction of the brain or retina. Criteria:(1) acute onset of a new focal neurological deficit with clinical or imaging evidence of infarction lasting more than 24 hours and not attributable to a non-ischemic etiology (not associated with brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease); or (2) acute onset of a new focal neurological deficit and not attributable to a non-ischemic etiology lasting less than 24 hours, but accompanied by neuroimaging evidence of new brain infarction; or, (3) rapid worsening of an existing focal neurological deficit (an increase in NIHSS of ≥4 on the basis of a primary ischemic stroke, excluding hemorrhagic transformation or symptomatic cranial disease after infarction) lasting more than 24 hours and not attributable to a non-ischemic etiology, and accompanied by new ischemic changes on brain MRI or CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>90 days</time_frame>
    <description>A neurological deficit of sudden onset, resolving completely, attributed to focal brain or retinal ischemia without evidence of associated acute focal infarction of the brain. Criteria: rapid onset of a focal neurological deficit that is without evidence of acute focal infarction of the brain, and is not attributable to a non-ischemic etiology (brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>90 days</time_frame>
    <description>Acute myocardial infarction is diagnosed by the third edition of the international general diagnostic criteria (Glob Heart. 2012 Dec;7(4):275-95)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>90 days</time_frame>
    <description>Vascular death includes stroke, sudden cardiac death, acute myocardial infarction, heart failure, pulmonary embolism, heart / cerebrovascular intervention or surgery (death unrelated to acute MI) and other cardiovascular causes of death [such as: Arrhythmia irrelevant with sudden cardiac death, aortic aneurysm rupture, or peripheral artery disease. Any death of unknown/unclear cause that occurs within 30 days after stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery will be regarded as death due to stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>90 days</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poor functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>The modified Rankin Scale (mRS)= 2-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5D scale)</measure>
    <time_frame>90 days</time_frame>
    <description>EQ-5D scale index score ≤0.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of atherosclerotic plaque using high-resolution magnetic resonance imaging (HR-MRI)</measure>
    <time_frame>90 days</time_frame>
    <description>Change of atherosclerotic plaque using high-resolution magnetic resonance 。 Patients in HR-MRI subgroup only</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">6100</enrollment>
  <condition>Acute Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>DAPT + immediate high-intensity statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPT + delayed high-intensity statin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin+immediate high-intensity statin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin+delayed high-intensity statin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive antiplatelet</intervention_name>
    <description>Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day&#xD;
Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day&#xD;
Day22 - 90: clopidogrel 75mg/day+aspirin placebo</description>
    <arm_group_label>DAPT + delayed high-intensity statin</arm_group_label>
    <arm_group_label>DAPT + immediate high-intensity statin</arm_group_label>
    <other_name>Dual antiplatelet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard antiplatelet</intervention_name>
    <description>Day 1: Aspirin 100-300mg/day + clopidogrel placebo&#xD;
Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo</description>
    <arm_group_label>Aspirin+delayed high-intensity statin</arm_group_label>
    <arm_group_label>Aspirin+immediate high-intensity statin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate high-intensity statin</intervention_name>
    <description>Day 1 - 21：Atorvastatin calcium 80mg/day&#xD;
Day 22 - 90：Atorvastatin calcium 40mg/day</description>
    <arm_group_label>Aspirin+immediate high-intensity statin</arm_group_label>
    <arm_group_label>DAPT + immediate high-intensity statin</arm_group_label>
    <other_name>Immediate Atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delayed high-intensity statin</intervention_name>
    <description>Day 1 - 3：Atorvastatin calcium placebo&#xD;
Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo&#xD;
Day 22 - 90：Atorvastatin calcium 40mg/day</description>
    <arm_group_label>Aspirin+delayed high-intensity statin</arm_group_label>
    <arm_group_label>DAPT + delayed high-intensity statin</arm_group_label>
    <other_name>Delayed Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age :35-80 years old , male or female;&#xD;
&#xD;
          2. Any of the following three two situations:&#xD;
&#xD;
        (1) Mild ischemic stroke (NIHSS 4 to 5 points) within 24 hours of onset meets any of the&#xD;
        following imaging conditions:&#xD;
&#xD;
          1. Acute single cerebral infarction with criminal intracranial and extracranial&#xD;
             atherosclerotic stenosis (stenosis rate ≥50%)&#xD;
&#xD;
          2. Acute multiple cerebral infarction (considered to be caused by large artery&#xD;
             atherosclerosis, including non-stenotic vulnerable plaque)&#xD;
&#xD;
        Or (2) Moderate-to-high-risk TIA (ABCD2≥4 points) or mild ischemic stroke (NIHSS≤5 points)&#xD;
        within 24 to 72 hours of onset meets any of the following imaging conditions:&#xD;
&#xD;
          1. Medium and high risk TIA with criminal intracranial and extracranial atherosclerotic&#xD;
             stenosis (stenosis rate ≥50%)&#xD;
&#xD;
          2. Acute single cerebral infarction with criminal intracranial and extracranial&#xD;
             atherosclerotic stenosis (stenosis rate ≥50%)&#xD;
&#xD;
          3. Acute multiple cerebral infarction (considered to be caused by large artery&#xD;
             atherosclerosis, including non-stenotic vulnerable plaque)&#xD;
&#xD;
        The rate of intracranial artery stenosis is assessed by MRA, CTA, or DSA according to WASID&#xD;
        standards; the rate of extracranial artery stenosis is assessed by carotid ultrasound,&#xD;
        CEMRA, CTA or DSA, according to NASCET standards; 3. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Specific cardiogenic ischemic cerebrovascular diseases(eg. combined with atrial&#xD;
             fibrillation, heart valve prosthesis, atrial myxoma, endocarditis, etc.)&#xD;
&#xD;
          2. Other ischemic cerebrovascular diseases with specific causes (eg. aortic dissection,&#xD;
             vasculitis, vascular malformation, etc.)&#xD;
&#xD;
          3. Non-cerebral vascular disease (eg. intracranial tumors, multiple sclerosis)&#xD;
&#xD;
          4. Cerebral infarction of large area (infarct size greater than half the single lobe&#xD;
             area)&#xD;
&#xD;
          5. CT indicating hemorrhagic transformation of cerebral infarction before randomization&#xD;
&#xD;
          6. Patients with pre-existing contraindications of using clopidogrel, aspirin or statin&#xD;
             drugs:&#xD;
&#xD;
             Known history of allergy ; Severe heart failure and asthma ; Coagulant disorders and&#xD;
             systemic bleeding ; Pre-existing drug - induced blood system disease or abnormal liver&#xD;
             function ; Leukopenia (&lt; 2×109/l) or thrombocytopenia (&lt;100×109/l) ; active liver&#xD;
             disease ; pregnancy or lactation period ; Severe heart failure：New York Heart&#xD;
             Association (NYHA) Functional Classification III and IV&#xD;
&#xD;
          7. MRS &gt; 2 before the onset&#xD;
&#xD;
          8. Use of intravenous or arterial thrombolysis intravascular therapy or bridge therapy&#xD;
             after onset&#xD;
&#xD;
          9. Use of defibrinating therapy like snake venom, defibrase, lumbrokinase, etc. or use of&#xD;
             anticoagulant therapy like argatroban, or use of antiplatelet therapy except&#xD;
             clopidogrel and aspirin, such as tirofiban, ticagrelor, ozagrel, and so on after&#xD;
             onset.&#xD;
&#xD;
         10. Creatine Kinase(CK) more than 5 times of the upper limit of normal value after onset&#xD;
&#xD;
         11. Use of drugs affecting the metabolism of statins such as immune-suppressive drugs,&#xD;
             antifungal agents, or fibrates drugs and so on, within 14 days before randomization.&#xD;
&#xD;
         12. Severe hepatic or renal insufficiency (Note: Severe hepatic insufficiency refers to&#xD;
             the ALT value &gt; 2 times the upper limit of normal value or AST times &gt; 2 times the&#xD;
             upper limit of normal value; Severe hepatic insufficiency is refers to creatinine&#xD;
             values &gt; 1.5 times he upper limit of normal value or GFR &lt; 40 ml/min/1.73 m2)&#xD;
&#xD;
         13. Usage of dual antiplatelet therapy with aspirin plus clopidogrel within 14 days before&#xD;
             randomization. (patients who received dual antiplatelet therapy (aspirin combined with&#xD;
             clopidogrel) but did not use clopidogrel with loading dose after onset were excluded)&#xD;
&#xD;
         14. Use of Intensive statin therapy within 14 days before randomization（atorvastatin&#xD;
             ≥40mg/d or rosuvastatin ≥ 20mg/d）.&#xD;
&#xD;
         15. Pre-existing intracranial hemorrhage（eg. ICH, SAH）&#xD;
&#xD;
         16. Gastrointestinal bleeding or major surgery occurred within 90 days before&#xD;
             randomization.&#xD;
&#xD;
         17. Pre-existing extracranial angioplasty or vascular surgery&#xD;
&#xD;
         18. Anticipated requirement for long-term non-study antiplatelet drugs, or non-steroid&#xD;
             anti-inflammatory drugs.&#xD;
&#xD;
         19. Experimental drugs need to stop due to angioplasty or vascular surgery, which was&#xD;
             planned or likely to perform within 90 days after randomization&#xD;
&#xD;
         20. Patients with severe disease expected to live for less than 90 days&#xD;
&#xD;
         21. Pregnant or childbearing-age women who have no effective contraceptives or positive&#xD;
             pregnancy test records&#xD;
&#xD;
         22. Patients who are undergoing experimental drugs or device tests&#xD;
&#xD;
         23. Unable to finish the follow-up of 90 days due to geographical factor or other&#xD;
             reasons（eg. dementia, alcoholism, substance abuse, severe mental disease, etc.）&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yilong Wang, MD, PhD</last_name>
    <phone>0086-010-67092222</phone>
    <email>yilong528@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yilong Wang, M.D.</last_name>
      <email>yilong528@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anshan Central Hospital</name>
      <address>
        <city>Anshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Hu</last_name>
      <email>huwei5930530@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Anshan Iron and Steel Company</name>
      <address>
        <city>Anshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guimei Zhao</last_name>
      <phone>18941245317</phone>
      <email>wygraduation@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anyang People's Hospital</name>
      <address>
        <city>Anyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingcheng Yang</last_name>
      <phone>13503728378</phone>
      <email>1317733903@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baoding First Central Hospital</name>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei Wang</last_name>
      <email>w_z_h_01@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hepingli Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Li</last_name>
      <phone>13691089898</phone>
      <email>13691089898@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benxi Central Hospital</name>
      <address>
        <city>Benxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengguang Song</last_name>
      <phone>15041488936</phone>
      <email>scg2011@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Tan</last_name>
      <email>tanhong1968@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second people's Hospital of Hunan Province</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosong Huang</last_name>
      <email>Huangxs-0819@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Third Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Yuan</last_name>
      <phone>15343319313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhi Medical College Affiliated Heping Hospital</name>
      <address>
        <city>Changzhi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yufeng Wang</last_name>
      <phone>13834770505</phone>
      <email>anycall98@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhi People's Hospital</name>
      <address>
        <city>Changzhi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lifang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lu'an Group General Hospital</name>
      <address>
        <city>Changzhi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbin Wu</last_name>
      <email>13935526973@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhou Second People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenwei Yun</last_name>
      <email>xjyww@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhou Wujin Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafeng Jin</last_name>
      <phone>13701498182</phone>
      <email>jhf558@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Sanxia Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengli Chen</last_name>
      <email>2271487396@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital affiliated to the Army Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kangning Chen</last_name>
      <email>ckn_640827@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Central Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cui Wang</last_name>
      <phone>15509850795</phone>
      <email>wangc817@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Friendship Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Li</last_name>
      <email>xhlihh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second people's Hospital of Dalian</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Qu</last_name>
      <email>zhongyi-100@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Dalian University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Bai</last_name>
      <email>yingbai@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Dali Bai Autonomous Prefecture</name>
      <address>
        <city>Dali</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liu</last_name>
      <email>13987205133@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Datong Third People's Hospital</name>
      <address>
        <city>Datong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Cui</last_name>
      <email>18503528899@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dazhou Central Hospital</name>
      <address>
        <city>Dazhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunpin Liu</last_name>
      <email>824826@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongguan Hong Wah hospital</name>
      <address>
        <city>Dongguan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changqing Xu</last_name>
      <phone>13829199811</phone>
      <email>453624572@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donghua Hospital</name>
      <address>
        <city>Dongguan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Che</last_name>
      <email>81369717@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongyang People's Hospital</name>
      <address>
        <city>Dongyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongjuan Xu</last_name>
      <phone>13588620108</phone>
      <email>xdj0108@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Dongying District</name>
      <address>
        <city>Dongying</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongping Jiang</last_name>
      <email>15698085639@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Fushun Mining Bureau</name>
      <address>
        <city>Fushun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanfeng Lv</last_name>
      <email>lyf198210dou@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuxin Mining Group General Hospital</name>
      <address>
        <city>Fuxin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingjie Duan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanxi Mountain hospital in Guangxi District</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang</last_name>
      <email>wangjundoc@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Second Hospital</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Sun</last_name>
      <phone>13985140155</phone>
      <email>956350990@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of the General Administration of agriculture and reclamation of Heilongjiang</name>
      <address>
        <city>Ha'erbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunshan Jin</last_name>
      <email>jss711210@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Handan Central Hospital</name>
      <address>
        <city>Handan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juntao Li</last_name>
      <email>504422425@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Handan First Hospital</name>
      <address>
        <city>Handan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiping Wu</last_name>
      <phone>18830056789</phone>
      <email>WYP5@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiujuan Song</last_name>
      <phone>13313111003</phone>
      <email>songxiujuan1@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hengshui Sixth People's Hospital</name>
      <address>
        <city>Hengshui</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linying Gui</last_name>
      <phone>13785883369</phone>
      <email>JZGLY0321@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanhua Hospital Affiliated to Nanhua University</name>
      <address>
        <city>Hengyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zou</last_name>
      <phone>18973405863</phone>
      <email>zouwei415@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Inner Mongolia Autonomous Region people's Hospital</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runxiu Zhu</last_name>
      <phone>18047191885</phone>
      <email>zhurunxiu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Jiamusi University</name>
      <address>
        <city>Jiamusi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoying Sheng</last_name>
      <email>shengbaoying123@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiamusi Central Hospital</name>
      <address>
        <city>Jiamusi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Chen</last_name>
      <email>ZXYYSJN1K8602139@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Electric Power Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peimin Chen</last_name>
      <email>chenpeimin@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinlin Central Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aixuan Wei</last_name>
      <email>595892279@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinlin People's Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Liu</last_name>
      <email>jljllhy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qianfo Hill Hospital of Shandong Province</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meijia Zhu</last_name>
      <email>zhumeijia1818@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Transportation Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongtao Lv</last_name>
      <phone>13969088522</phone>
      <email>fxx_771108@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiujiang University</name>
      <address>
        <city>Jiujiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Yin</last_name>
      <email>xiaopingbuxiao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jixi People's Hospital</name>
      <address>
        <city>Jixi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Liu</last_name>
      <phone>15146763335</phone>
      <email>wxp124@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaifeng Central Hospital</name>
      <address>
        <city>Kai Feng</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Ma</last_name>
      <phone>13353813596</phone>
      <email>xiangxin2007@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng Brain Hospital</name>
      <address>
        <city>Liaocheng</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhangyong Xia</last_name>
      <email>xiazhangyong2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng Second People's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinqiang Wang</last_name>
      <phone>13562062933</phone>
      <email>13562062933@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoyang Central Hospital</name>
      <address>
        <city>Liaoyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zheng</last_name>
      <email>1762172231@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linfen People's Hospital</name>
      <address>
        <city>Linfen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunping Chen</last_name>
      <phone>15034329988</phone>
      <email>Pingchun9136@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Shangguan</last_name>
      <phone>13608467154</phone>
      <email>shangguanwen2004@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzhou Hospital of traditional Chinese Medicine</name>
      <address>
        <city>Luzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yang</last_name>
      <phone>18015758098</phone>
      <email>18015758098@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mishan People's Hospital</name>
      <address>
        <city>Mishan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanren Zhang</last_name>
      <phone>13945862066</phone>
      <email>MSZYR2066@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mudanjiang Second People's Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumin Yu</last_name>
      <email>yfm19651208@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoliang Lou</last_name>
      <email>2860134816@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youqing Deng</last_name>
      <email>youqing1969@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejun Li</last_name>
      <phone>13951515606</phone>
      <email>lilejjun999@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Li Huili Hospital of Ningbo Medical Center</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Zhao</last_name>
      <phone>13905748231</phone>
      <email>zhaojialin2016@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Second Hospital</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenke Hong</last_name>
      <phone>17706610751</phone>
      <email>hongwk@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningde People's Hospital</name>
      <address>
        <city>Ningde</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoping Zou</last_name>
      <email>zoug_ping@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panjin Central Hospital</name>
      <address>
        <city>Panjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhua Zhou</last_name>
      <phone>18942756111</phone>
      <email>pjlizhuo@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pindingshan First People's Hospital</name>
      <address>
        <city>Pingdingshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjun Xue</last_name>
      <email>xuewj08@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qiqihar First Hospital</name>
      <address>
        <city>Qiqihar</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuerong Qiu</last_name>
      <phone>18545606777</phone>
      <email>445619227@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruzhou First People's Hospital</name>
      <address>
        <city>Rizhao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Wang</last_name>
      <phone>13937570507</phone>
      <email>wangc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanmenxia Central Hospital</name>
      <address>
        <city>Sanmenxia</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shufang Yao</last_name>
      <phone>13949761600</phone>
      <email>53754786@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fifth People's Hospital of Shanghai City, affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danhong Wu</last_name>
      <email>kathywuxue@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianrong Liu</last_name>
      <email>liujr300@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongfang Li</last_name>
      <phone>15934126475</phone>
      <email>lidongfang898@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengzhou People's Hospital</name>
      <address>
        <city>Shaoxing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingsong Wang</last_name>
      <phone>13757537585</phone>
      <email>drwangqs@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Agriculture and Reclamation Bei'an Administration Central Hospital</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhong Song</last_name>
      <phone>15145609213</phone>
      <email>190833831@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijie Ren</last_name>
      <phone>13631605966</phone>
      <email>13631605966@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Pingan Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weigang Xiao</last_name>
      <phone>18031915736</phone>
      <email>xiaoyan144@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Fang</last_name>
      <email>fangqi_008@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunfeng Liu</last_name>
      <email>liucf20@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou First People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Wang</last_name>
      <phone>13606688818</phone>
      <email>Welson1980@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of North China Polytechnic University</name>
      <address>
        <city>Tangshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <phone>15383056688</phone>
      <email>liubintsh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangshan Workers' Hospital</name>
      <address>
        <city>Tangshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Liu</last_name>
      <email>angel.jsea@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Fourth Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Wang</last_name>
      <phone>13820209241</phone>
      <email>wlj2004497@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tieling Central Hospital</name>
      <address>
        <city>Tieling</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lixia Wang</last_name>
      <email>511760961@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaomi People's Hospital</name>
      <address>
        <city>Weifang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanhao Li</last_name>
      <email>liquanhao120@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Wendeng District</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinguo Zhao</last_name>
      <phone>13561852177</phone>
      <email>zjg52177@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Zhang</last_name>
      <email>zhzhqing1990@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Central Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin Jing</last_name>
      <email>jing51118@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Academy of Medical Sciences, Wuwei</name>
      <address>
        <city>Wuwei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenshuai Zhang</last_name>
      <email>934138494@qq.cm</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Zhang</last_name>
      <phone>15961896462</phone>
      <email>wangfeng717798@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Second People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunan Lu</last_name>
      <phone>15251643918</phone>
      <email>tmadoc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an 141 hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuwu Liu</last_name>
      <email>xfyynei2ke@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xian First Hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songdi Wu</last_name>
      <email>wusongdi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxiang Central Hospital</name>
      <address>
        <city>Xinxiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhifang Wang</last_name>
      <email>wzf2146@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinyang Central Hospital</name>
      <address>
        <city>Xinyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Chan</last_name>
      <email>13939702696@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuchang Central Hospital</name>
      <address>
        <city>Xuchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxun Fan</last_name>
      <phone>13938916688</phone>
      <email>wyinsh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Xuzhou Mining Group</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiue Wei</last_name>
      <phone>15052006672</phone>
      <email>wxeqq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou First People's Hospital</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing He</last_name>
      <phone>15052001307</phone>
      <email>heqing80000@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital Affiliated to Qiingdao University</name>
      <address>
        <city>Yantai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuwen Sun</last_name>
      <email>sunxuwen@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yibin First People's Hospital</name>
      <address>
        <city>Yibin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wei</last_name>
      <email>461301535@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yichang First People's Hospital</name>
      <address>
        <city>Yichang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqin Hu</last_name>
      <email>453852003@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yingkou Central Hospital</name>
      <address>
        <city>Yingkou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Song</last_name>
      <email>yk_sl@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yueyang Hospital of integrated traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Yueyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Han</last_name>
      <phone>13917022800</phone>
      <email>hanyan.2006@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dehong People's Hospital of Yunnan</name>
      <address>
        <city>Yunnan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Wang</last_name>
      <email>wangming7906@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zaozhuang Mining Group Zaozhuang hospital</name>
      <address>
        <city>Zaozhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Feng</last_name>
      <email>fl200410@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang First People's Hospital</name>
      <address>
        <city>Zhangjiagang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuyi Wu</last_name>
      <phone>13812843138</phone>
      <email>qiuyi1028@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Zhangjiagang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Sun</last_name>
      <phone>13773241027</phone>
      <email>sunyaming2001@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Workers' Hospital of Hebei iron and Steel Group Xuanhua iron and Steel Co., Ltd.</name>
      <address>
        <city>Zhangjiakou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yimin Xie</last_name>
      <email>xym13731387896@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of the Yellow River</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinxia Wei</last_name>
      <phone>13333717870</phone>
      <email>weixinxia0214@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengzhou First People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoman Zhang</last_name>
      <email>zhangxiaoman2@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaiyu Guo</last_name>
      <email>yuming7251@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhoukou Yongshan hospital</name>
      <address>
        <city>Zhoukou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinqi Fan</last_name>
      <email>765288157@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhumadian Central Hospital</name>
      <address>
        <city>Zhumadian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihua Long</last_name>
      <email>lzh882@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zigong First People's Hospital</name>
      <address>
        <city>Zigong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linmin Haung</last_name>
      <email>2856343519@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>March 27, 2021</last_update_submitted>
  <last_update_submitted_qc>March 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>yilong Wang</investigator_full_name>
    <investigator_title>Vice President of Beijing Tiantan Hospital</investigator_title>
  </responsible_party>
  <keyword>Acute Stroke</keyword>
  <keyword>Transient Ischemic Attack</keyword>
  <keyword>Antiplatelet Therapy</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Double Blind Study</keyword>
  <keyword>Multicenter Study</keyword>
  <keyword>Symptomatic Extracranial or Intracranial Arterial Stenosis</keyword>
  <keyword>Statin Therapy</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

